FMFarzaneh Mashayekhi

Farzaneh Mashayekhi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farzaneh Mashayekhi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skin Stem Cells in Iran

    by Mohammad Ali Nilforoushzadeh, Mohammad Amir Amirkhani, Farnoosh Seirafianpour, Farzaneh Mashayekhi, Pardis Hejazi, Azadeh Goodarzi

  • Open Access

    COVID‐19 and COVID‐19 vaccine‐related dermatological reactions: An interesting case series with a narrative review of the potential critical and non‐critical mucocutaneous adverse effects related to virus, therapy, and the vaccination

    by Arash Pour Mohammad, Farzaneh Mashayekhi, Farnoosh Seirafianpour, Milad Gholizadeh Mesgarha, Azadeh Goodarzi

    This narrative review article was conducted to lay out a summarized but exhaustive review of current literature over mucocutaneous manifestations in 4 dimensions of SARS‐CoV‐2 pandemic: virus itself, treatment‐related, vaccine‐induced, and alteration of chronic dermatologic diseases following infection. Virus and vaccine‐related were mainly self‐limited and non‐severe. Treatment‐related reactions could be life‐threatening.


  • Open Access

    Severe and life‐threatening COVID‐19‐related mucocutaneous eruptions: A systematic review

    by Farzaneh Mashayekhi, Farnoosh Seirafianpour, Arash Pour Mohammad, Azadeh Goodarzi

    Objectives Earlier diagnosis and the best management of virus-related, drug-related or mixed severe potentially life-threatening mucocutaneous reactions of COVID-19 patients are of great concern. These patients, especially hospitalized cases, are usually in a complicated situation (due to multi-organ failures), which makes their management more challenging. In such consultant cases, achieving by the definite beneficial management strategies that therapeutically address all concurrent comorbidities are really hard to reach or even frequently impossible. Methods According to the lack of any relevant systematic review, we thoroughly searched the databases until October/5/2020and finally found 57 articles including 93 patients. It is needed to know clinical presentations of these severe skin eruptions, signs and symptoms of COVID in these patients, time of skin rash appearance, classifying drug-related or virus-related skin lesions, classifying the type of skin rash, patients’ outcome and concurrent both COVID-19 therapy and skin rash treatment. Result Severe and potential life-threatening mucocutaneous dermatologic manifestations of COVID-19 usually may be divided into three major categories: virus-associated, drug-associated, and those with uncertainty about the exact origin. Angioedema, vascular lesions, toxic shock syndrome, erythroderma, DRESS, hemorrhagic bulla, AGEP, EM, SJS and TEN, generalized pustular figurate erythema were the main entities found as severe dermatologic reactions in all categories. Conclusion We can conclude vascular injuries may be the most common cause of severe dermatologic manifestations of COVID-19, which is concordant with many proposed hypercoagulation tendency and systemic inflammatory response syndrome as one of the most important pathomechanism of COVID-19so the skin may show these features in various presentations and degrees.